Woodline Partners LP Buys 251,924 Shares of Janux Therapeutics, Inc. (NASDAQ:JANX)

Woodline Partners LP grew its holdings in shares of Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) by 15.7% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 1,852,187 shares of the company's stock after acquiring an additional 251,924 shares during the quarter. Janux Therapeutics accounts for approximately 0.7% of Woodline Partners LP's holdings, making the stock its 15th biggest holding. Woodline Partners LP owned approximately 3.53% of Janux Therapeutics worth $99,166,000 at the end of the most recent quarter.

Several other large investors have also recently made changes to their positions in JANX. Barclays PLC raised its holdings in shares of Janux Therapeutics by 496.5% during the third quarter. Barclays PLC now owns 174,061 shares of the company's stock valued at $7,907,000 after purchasing an additional 144,883 shares during the last quarter. Franklin Resources Inc. boosted its position in shares of Janux Therapeutics by 64.5% during the third quarter. Franklin Resources Inc. now owns 18,983 shares of the company's stock worth $937,000 after acquiring an additional 7,442 shares during the last quarter. Avanza Fonder AB purchased a new stake in Janux Therapeutics during the fourth quarter valued at $139,000. China Universal Asset Management Co. Ltd. raised its stake in shares of Janux Therapeutics by 10.9% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 11,128 shares of the company's stock valued at $596,000 after acquiring an additional 1,095 shares during the period. Finally, Chicago Capital LLC purchased a new position in Janux Therapeutics in the 4th quarter worth about $230,000. 75.39% of the stock is owned by hedge funds and other institutional investors.

Janux Therapeutics Trading Down 0.5%

Shares of JANX opened at $24.17 on Tuesday. The firm has a market cap of $1.43 billion, a P/E ratio of -20.66 and a beta of 3.24. Janux Therapeutics, Inc. has a 12-month low of $22.48 and a 12-month high of $71.71. The company's 50-day moving average price is $28.50 and its 200 day moving average price is $40.33.

Janux Therapeutics (NASDAQ:JANX - Get Free Report) last released its earnings results on Thursday, May 8th. The company reported ($0.38) earnings per share for the quarter, topping analysts' consensus estimates of ($0.43) by $0.05. Janux Therapeutics had a negative net margin of 463.91% and a negative return on equity of 10.47%. Equities research analysts forecast that Janux Therapeutics, Inc. will post -1.38 earnings per share for the current year.

Insider Activity

In related news, Director Ra Capital Management, L.P. acquired 341,742 shares of the company's stock in a transaction that occurred on Wednesday, March 5th. The stock was purchased at an average price of $30.64 per share, for a total transaction of $10,470,974.88. Following the transaction, the director now owns 9,658,988 shares in the company, valued at $295,951,392.32. This trade represents a 3.67% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Andrew Hollman Meyer sold 3,333 shares of the firm's stock in a transaction dated Thursday, May 1st. The stock was sold at an average price of $32.03, for a total value of $106,755.99. Following the completion of the sale, the insider now directly owns 82,139 shares in the company, valued at approximately $2,630,912.17. The trade was a 3.90% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 10,001 shares of company stock valued at $313,964. 8.10% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

A number of analysts have recently weighed in on the stock. Wedbush restated an "outperform" rating and issued a $76.00 price target (up from $75.00) on shares of Janux Therapeutics in a report on Friday, February 28th. Scotiabank reduced their price target on shares of Janux Therapeutics from $62.00 to $41.00 and set a "sector perform" rating for the company in a research report on Friday, February 28th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $70.00 target price on shares of Janux Therapeutics in a report on Monday, March 3rd. One research analyst has rated the stock with a hold rating, eight have given a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of "Buy" and a consensus target price of $95.25.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.

Want to see what other hedge funds are holding JANX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.